Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.

Karkera JD, Cardona GM, Bell K, Gaffney D, Portale JC, Santiago-Walker A, Moy CH, King P, Sharp M, Bahleda R, Luo FR, Alvarez JD, Lorenzi MV, Platero SJ.

Mol Cancer Ther. 2017 Aug;16(8):1717-1726. doi: 10.1158/1535-7163.MCT-16-0518. Epub 2017 Apr 17.

2.

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.

Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV.

Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24.

3.

Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.

Coiffier B, Li W, Henitz ED, Karkera JD, Favis R, Gaffney D, Shapiro A, Theocharous P, Elsayed YA, van de Velde H, Schaffer ME, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Romejko-Jarosinska J, de Vos S, Crump M, Shpilberg O, Zinzani PL, Cakana A, Esseltine DL, Mulligan G, Ricci D.

Clin Cancer Res. 2013 May 1;19(9):2551-61. doi: 10.1158/1078-0432.CCR-12-3069. Epub 2013 Apr 2.

4.

A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication.

Arcos-Burgos M, Jain M, Acosta MT, Shively S, Stanescu H, Wallis D, Domené S, Vélez JI, Karkera JD, Balog J, Berg K, Kleta R, Gahl WA, Roessler E, Long R, Lie J, Pineda D, Londoño AC, Palacio JD, Arbelaez A, Lopera F, Elia J, Hakonarson H, Johansson S, Knappskog PM, Haavik J, Ribases M, Cormand B, Bayes M, Casas M, Ramos-Quiroga JA, Hervas A, Maher BS, Faraone SV, Seitz C, Freitag CM, Palmason H, Meyer J, Romanos M, Walitza S, Hemminger U, Warnke A, Romanos J, Renner T, Jacob C, Lesch KP, Swanson J, Vortmeyer A, Bailey-Wilson JE, Castellanos FX, Muenke M.

Mol Psychiatry. 2010 Nov;15(11):1053-66. doi: 10.1038/mp.2010.6. Epub 2010 Feb 16.

5.

Cumulative ligand activity of NODAL mutations and modifiers are linked to human heart defects and holoprosencephaly.

Roessler E, Pei W, Ouspenskaia MV, Karkera JD, Veléz JI, Banerjee-Basu S, Gibney G, Lupo PJ, Mitchell LE, Towbin JA, Bowers P, Belmont JW, Goldmuntz E, Baxevanis AD, Feldman B, Muenke M.

Mol Genet Metab. 2009 Sep-Oct;98(1-2):225-34. doi: 10.1016/j.ymgme.2009.05.005. Epub 2009 May 27.

6.

Reduced NODAL signaling strength via mutation of several pathway members including FOXH1 is linked to human heart defects and holoprosencephaly.

Roessler E, Ouspenskaia MV, Karkera JD, Vélez JI, Kantipong A, Lacbawan F, Bowers P, Belmont JW, Towbin JA, Goldmuntz E, Feldman B, Muenke M.

Am J Hum Genet. 2008 Jul;83(1):18-29. doi: 10.1016/j.ajhg.2008.05.012. Epub 2008 Jun 5.

7.

Loss-of-function mutations in growth differentiation factor-1 (GDF1) are associated with congenital heart defects in humans.

Karkera JD, Lee JS, Roessler E, Banerjee-Basu S, Ouspenskaia MV, Mez J, Goldmuntz E, Bowers P, Towbin J, Belmont JW, Baxevanis AD, Schier AF, Muenke M.

Am J Hum Genet. 2007 Nov;81(5):987-94. Epub 2007 Sep 28.

8.

Novel mutation in sonic hedgehog in non-syndromic colobomatous microphthalmia.

Schimmenti LA, de la Cruz J, Lewis RA, Karkera JD, Manligas GS, Roessler E, Muenke M.

Am J Med Genet A. 2003 Jan 30;116A(3):215-21.

PMID:
12503095
9.

The genomic structure, chromosomal localization, and analysis of SIL as a candidate gene for holoprosencephaly.

Karkera JD, Izraeli S, Roessler E, Dutra A, Kirsch I, Muenke M.

Cytogenet Genome Res. 2002;97(1-2):62-7.

PMID:
12438740
10.

Cathepsin B and complement C3 are major comigrants in the estrogen-induced peroxidase fraction of rat uterine fluid.

Balan KV, Hollis VW, Eckberg WR, Ayorinde F, Karkera JD, Wyche JH, Anderson WA.

J Submicrosc Cytol Pathol. 2001 Jul;33(3):221-30.

PMID:
11846090
11.

CFC1 mutations in patients with transposition of the great arteries and double-outlet right ventricle.

Goldmuntz E, Bamford R, Karkera JD, dela Cruz J, Roessler E, Muenke M.

Am J Hum Genet. 2002 Mar;70(3):776-80. Epub 2002 Jan 17.

12.

Association study on the DUSP6 gene, an affective disorder candidate gene on 12q23, performed by using fluorescence resonance energy transfer-based melting curve analysis on the LightCycler.

Toyota T, Watanabe A, Shibuya H, Nankai M, Hattori E, Yamada K, Kurumaji A, Karkera JD, Detera-Wadleigh SD, Yoshikawa T.

Mol Psychiatry. 2000 Sep;5(5):489-494.

PMID:
11035444
13.

Association study on the DUSP6 gene, an affective disorder candidate gene on 12q23, performed by using fluorescence resonance energy transfer-based melting curve analysis on the LightCycler.

Toyota T, Watanabe A, Shibuya H, Nankai M, Hattori E, Yamada K, Kurumaji A, Karkera JD, Detera-Wadleigh SD, Yoshikawa T.

Mol Psychiatry. 2000 Sep;5(5):461, 489-94.

PMID:
11032376
14.

Missense mutation of the MET gene detected in human glioma.

Moon YW, Weil RJ, Pack SD, Park WS, Pak E, Pham T, Karkera JD, Kim HK, Vortmeyer AO, Fuller BG, Zhuang Z.

Mod Pathol. 2000 Sep;13(9):973-7.

15.

Refinement of regions with allelic loss on chromosome 18p11.2 and 18q12.2 in esophageal squamous cell carcinoma.

Karkera JD, Ayache S, Ransome RJ Jr, Jackson MA, Elsayem AF, Sridhar R, Detera-Wadleigh SD, Wadleigh RG.

Clin Cancer Res. 2000 Sep;6(9):3565-9.

16.

Genomic structure and novel variants of myo-inositol monophosphatase 2 (IMPA2).

Yoshikawa T, Padigaru M, Karkera JD, Sharma M, Berrettini WH, Esterling LE, Detera-Wadleigh SD.

Mol Psychiatry. 2000 Mar;5(2):165-71.

PMID:
10822344
17.

Mutation analysis of oculopharyngeal muscular dystrophy in Hispanic American families.

Grewal RP, Karkera JD, Grewal RK, Detera-Wadleigh SD.

Arch Neurol. 1999 Nov;56(11):1378-81.

PMID:
10555658
18.

Radiation hybrid mapping of genes in the lithium-sensitive wnt signaling pathway.

Rhoads AR, Karkera JD, Detera-Wadleigh SD.

Mol Psychiatry. 1999 Sep;4(5):437-42.

PMID:
10523816
19.

Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations.

Pack SD, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P, Park WS, Pham T, Ault DO, Glaser M, Liotta L, Detera-Wadleigh SD, Wadleigh RG.

Genes Chromosomes Cancer. 1999 Jun;25(2):160-8.

PMID:
10338000
20.

Systematic screening of chromosome 18 for loss of heterozygosity in esophageal squamous cell carcinoma.

Karkera JD, Balan KV, Yoshikawa T, Lipman TO, Korman L, Sharma A, Patterson RH, Sani N, Detera-Wadleigh SD, Wadleigh RG.

Cancer Genet Cytogenet. 1999 May;111(1):81-6.

PMID:
10326596
21.

A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2.

Detera-Wadleigh SD, Badner JA, Berrettini WH, Yoshikawa T, Goldin LR, Turner G, Rollins DY, Moses T, Sanders AR, Karkera JD, Esterling LE, Zeng J, Ferraro TN, Guroff JJ, Kazuba D, Maxwell ME, Nurnberger JI Jr, Gershon ES.

Proc Natl Acad Sci U S A. 1999 May 11;96(10):5604-9.

22.

Sequence of the human CALM II calmodulin gene promoter region.

Karkera JD, Friedberg F.

Mol Biol Rep. 1998 Jul;25(3):193-5.

PMID:
9700056
23.

Deletion of a consensus oestrogen response element half-site in the glucocorticoid receptor of human multiple myeloma.

Karkera JD, Taymans SE, Turner G, Yoshikawa T, Detera-Wadleigh SD, Wadleigh RG.

Br J Haematol. 1997 Nov;99(2):372-4.

PMID:
9375757
24.

Sequence of a fourth human CALM II-related pseudogene (CALM II psi4).

Karkera JD, Friedberg F.

Mamm Genome. 1996 Nov;7(11):863. No abstract available.

PMID:
8875900

Supplemental Content

Loading ...
Support Center